knowledge -WSS

knowledge

author：leisure time 2025-08-12 06:42:11 - browse：219

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Living with Fabry disease, a condition that causes chronic pain

WSS

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Charles Manson follower Leslie Van Houten released from prison after 53 years

STAT Summit: The economic case for universal basic health care

How AI can help patients find reliable information about doctors

Why 40% Americans with Parkinson’s don’t see a neurologist

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Wikipedia

knowledge

focus

Walensky prepares to leave CDC — and Congress — behind

Study: Pain burden is higher in Black NFL players than white ones

Walensky prepares to leave CDC — and Congress — behind

New research casts further doubt on a common procedure used with IVF

At least 13 dead in Texas as scorching temps continue

STAT Summit: Meghan O’Rourke on making chronic illness visible

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Jerome Adams on the need for new antivirals for Covid

CZI to create biohub to build anti

leisure time

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Readout: Friday, Oct. 20 biotech updates

Health tech investors get more selective as pandemic boom fades

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Why 40% Americans with Parkinson’s don’t see a neurologist

leisure time

leisure time

focus

explore